echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Nutrition News > New approach to anti-HIV antibody therapy shows promise in phase I clinical trial

    New approach to anti-HIV antibody therapy shows promise in phase I clinical trial

    • Last Update: 2022-05-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    AAV vectors can be safely used in the body to deliver DNA into cells, and two AAV-based gene therapies are currently FDA-approved


    The Phase 1 clinical trial enrolled eight HIV-infected adults who had been on stable antiretroviral therapy for at least 3 months


    "This work represents the first successful AAV-based production of monoclonal antibodies of any type by anyone," said co-author Alejandro B.


    The findings have broad clinical implications for the possible prevention or treatment of HIV and other infections, Balazs noted


    The technique was originally developed by Balazs as a postdoc in the laboratory of Nobel laureate Dr.


    Additional study authors include Joseph P.


    This work was supported by internal funding from the National Institute of Allergy and Infectious Diseases through the NIH Internal Research Program


    Journal Reference :

    1. Joseph P.



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.